Target
ERα
5 abstracts
Abstract
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).Org: Royal Marsden NHS Foundation Trust, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Eisai,
Abstract
Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer.Org: Compass Oncology/US Oncology Network, Accutar Biotechnology Inc.,
Abstract
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Royal Marsden NHS Foundation Trust, Lineberger Comprehensive Cancer Center,
Abstract
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).Org: Mayo Clinic, Rochester, MN, Phoenix, AZ, Jacksonville, FL, Clear Lake Oncology,
Abstract
Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.Org: Memorial Sloan Kettering Cancer Center, START Midwest, Grand Rapids, MI, Valkyrie Clinical Trials, Inc, Stanford Hospital & Clinics, Virginia Cancer Specialists,